Alpha-glucosidase

Results: 67



#Item
51Microsoft Word - CRW Final Report- Screening for Pompe Disease 06042013_FinalEdits_CLEAN.docx

Microsoft Word - CRW Final Report- Screening for Pompe Disease 06042013_FinalEdits_CLEAN.docx

Add to Reading List

Source URL: www.hrsa.gov

Language: English - Date: 2013-06-20 16:06:33
52EVIDENCE REVIEW: POMPE DISEASE

EVIDENCE REVIEW: POMPE DISEASE

Add to Reading List

Source URL: www.hrsa.gov

Language: English - Date: 2012-01-07 00:54:21
53February 26, 2013 Press Release Mitsubishi Tanabe Pharma Corporation TENELIA® 20mg tablets, a Treatment for Type 2 Diabetes Mellitus Application for Partial Change in Indications for Combination Therapy

February 26, 2013 Press Release Mitsubishi Tanabe Pharma Corporation TENELIA® 20mg tablets, a Treatment for Type 2 Diabetes Mellitus Application for Partial Change in Indications for Combination Therapy

Add to Reading List

Source URL: www.mt-pharma.co.jp

Language: English - Date: 2013-12-11 23:08:01
54PRECOSE® (acarbose tablets[removed]DESCRIPTION PRECOSE® (acarbose tablets) is an oral alpha-glucosidase inhibitor for use in the management of type 2 diabetes mellitus. Acarbose is an oligosaccharide which is obtained f

PRECOSE® (acarbose tablets[removed]DESCRIPTION PRECOSE® (acarbose tablets) is an oral alpha-glucosidase inhibitor for use in the management of type 2 diabetes mellitus. Acarbose is an oligosaccharide which is obtained f

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2012-03-01 15:12:58
55PRECOSE® (acarbose tablets[removed]DESCRIPTION PRECOSE® (acarbose tablets) is an oral alpha-glucosidase inhibitor for use in the management of type 2 diabetes mellitus. Acarbose is an oligosaccharide which is obtained fr

PRECOSE® (acarbose tablets[removed]DESCRIPTION PRECOSE® (acarbose tablets) is an oral alpha-glucosidase inhibitor for use in the management of type 2 diabetes mellitus. Acarbose is an oligosaccharide which is obtained fr

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2011-03-28 12:08:24
56LYSOSOMAL STORAGE DISORDER Quarterly Report PROFICIENCY TESTING Volume 2, No. 2

LYSOSOMAL STORAGE DISORDER Quarterly Report PROFICIENCY TESTING Volume 2, No. 2

Add to Reading List

Source URL: www.cdc.gov

Language: English - Date: 2013-05-21 09:46:35
57LYSOSOMAL STORAGE DISORDER Quarterly Report PROFICIENCY TESTING  August 2013

LYSOSOMAL STORAGE DISORDER Quarterly Report PROFICIENCY TESTING August 2013

Add to Reading List

Source URL: www.cdc.gov

Language: English - Date: 2013-08-26 07:08:24
58JANUARY[removed]UNDERSTANDING POMPE DISEASE Pompe (POM-pay) disease, also known as glycogen storage disease type II or acid maltase deficiency, is a

JANUARY[removed]UNDERSTANDING POMPE DISEASE Pompe (POM-pay) disease, also known as glycogen storage disease type II or acid maltase deficiency, is a

Add to Reading List

Source URL: www.niams.nih.gov

Language: English - Date: 2013-05-22 13:44:51
59Amicus Therapeutics Announces Second Quarter 2007 Financial Results

Amicus Therapeutics Announces Second Quarter 2007 Financial Results

Add to Reading List

Source URL: www.unitedpompe.com

Language: English - Date: 2011-12-11 11:39:13
60Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease CRANBURY, N.J., June 3, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company

Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease CRANBURY, N.J., June 3, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company

Add to Reading List

Source URL: www.unitedpompe.com

Language: English - Date: 2008-06-03 09:27:22